sir ephedrin oral liquid - search results

iotech pty ltd - sodium amidotrizoate, quantity: 370.5 mg/ml - oral liquid, solution - excipient ingredients: sorbitol; acesulfame potassium; quinoline yellow; methyl hydroxybenzoate; citric acid; purified water; flavour - ioscan is a contrast medium for computerised axial tomograpghy examination of the gastrointestinal tract. it should be made up with water prior to use, and administered orally. it is indicated primarily for use when barium sulphate is not appropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

zarontin syrup ethosuximide 250mg/5ml oral liquid bottle

clinect pty ltd - ethosuximide, quantity: 50 mg/ml - oral liquid, solution - excipient ingredients: citric acid monohydrate; saccharin sodium; sucrose; glycerol; sodium citrate dihydrate; sodium benzoate; purified water; flavour - zarontin is indicated for the control of petit mal epilepsy.

Australia - English - Department of Health (Therapeutic Goods Administration)

ursofalk ursodeoxycholic acid 250mg/5ml oral liquid bottle

dr falk pharma australia pty ltd - ursodeoxycholic acid, quantity: 50 mg/ml - oral liquid, suspension - excipient ingredients: purified water; sodium cyclamate; citric acid; sodium citrate dihydrate; xylitol; sodium chloride; glycerol; propylene glycol; benzoic acid; microcrystalline cellulose; carmellose sodium; flavour - treatment of chronic cholestatic liver diseases.

Australia - English - Department of Health (Therapeutic Goods Administration)

capoten captopril 5mg/ml oral liquid bottle

arrotex pharmaceuticals pty ltd - captopril, quantity: 5 mg/ml - oral liquid, solution - excipient ingredients: sodium benzoate; hydrochloric acid; sodium hydroxide; sodium citrate dihydrate; disodium edetate; purified water; citric acid - 1.hypertension: capoten (captopril) is indicated for the treatment of hypertension. in using capoten, consideration should be given to the risk of neutropenia/agranulocytosis (see precautions). capoten is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. 2. myocardial infarction: capoten is indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction less than or equal to 40%, and to reduce the incidence of overt heart failure and subsequent hospitalisations for congestive heart failure in these patients. the efficacy data for the use of captopril following myocardial infarction are strongest for initiation of therapy beyond 3 days post-infarct. 3. heart failure: capoten (captopril) is indicated for the treatment of heart failure. in symptomatic patients it is recommended that capoten be administered together with a diuretic. 4. diabetic nephropathy: capoten is indicated for the treatment of diabetic nephropathy in patients with type 1 insulin- dependent diabetes mellitus.